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Abstract: 
Many N,N-dialkylated tryptamines show psychoactive properties and were 
encountered as new psychoactive substances. The aims of the presented 
work were to study the phase I and II metabolism and the detectability in 
standard urine screening approaches (SUSA) of 5-methoxy-2-methyl-N,N-
diallyltryptamine (5-MeO-2-Me-DALT), 5-methoxy-2-methyl-N-allyl-N-
cyclohexyltryptamine (5-MeO-2-Me-ALCHT), and 5-methoxy-2-methyl-N,N-
diisopropyltryptamine (5-MeO-2-Me-DIPT) using GC-MS, LC-MSn, and LC-
HR-MS/MS. For metabolism studies, urine was collected over a 24-h period 
after administration of the compounds to male Wistar rats at 20 mg/kg 
body weight (BW). Phase I and II metabolites were identified after urine 
precipitation with acetonitrile by LC-HR-MS/MS. 5-MeO-2-Me-DALT (24 
phase I and 12 phase II metabolites), 5-MeO-2-Me-ALCHT (24 phase I and 
14 phase II metabolites), and 5-MeO-2-Me-DIPT (20 phase I and 11 phase 
II metabolites) were mainly metabolized by O-demethylation, 
hydroxylation, N-dealkylation, and combinations of them as well as by 
glucuronidation and sulfation of phase I metabolites. Incubations with 
mixtures of pooled human liver microsomes and cytosols (pHLM and pHLC) 
confirmed that the main metabolic reactions in humans and rats might be 
identical. Furthermore, initial CYP activity screenings revealed that CYP1A2, 
CYP2C19, CYP2D6, and CYP3A4 were involved in hydroxylation, CYP2C19 
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and CYP2D6 in O-demethylation, and CYP2C19, CYP2D6, and CYP3A4 in N-
dealkylation. For SUSAs, GC-MS, LC-MSn, and LC-HR-MS/MS were applied 
to rat urine samples after 1 or 0.1 mg/kg BW doses, respectively. In 
contrast to the GC-MS SUSA, both LC-MS SUSAs were able to detect an 
intake of 5-MeO-2-Me-ALCHT and 5-MeO-2-Me-DIPT via their metabolites 
following 1 mg/kg BW administrations and 5-MeO-2-Me-DALT following 0.1 
mg/kg BW dosage.  
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Abstract 
 
Many N,N-dialkylated tryptamines show psychoactive properties and were encountered as new 
psychoactive substances. The aims of the presented work were to study the phase I and II 
metabolism and the detectability in standard urine screening approaches (SUSA) of 5-methoxy-2-
methyl-N,N-diallyltryptamine (5-MeO-2-Me-DALT), 5-methoxy-2-methyl-N-allyl-N-
cyclohexyltryptamine (5-MeO-2-Me-ALCHT), and 5-methoxy-2-methyl-N,N-
diisopropyltryptamine (5-MeO-2-Me-DIPT) using GC-MS, LC-MSn, and LC-HR-MS/MS. For 
metabolism studies, urine was collected over a 24-h period after administration of the compounds to 
male Wistar rats at 20 mg/kg body weight (BW). Phase I and II metabolites were identified after 
urine precipitation with acetonitrile by LC-HR-MS/MS. 5-MeO-2-Me-DALT (24 phase I and 12 
phase II metabolites), 5-MeO-2-Me-ALCHT (24 phase I and 14 phase II metabolites), and 5-MeO-
2-Me-DIPT (20 phase I and 11 phase II metabolites) were mainly metabolized by O-demethylation, 
hydroxylation, N-dealkylation, and combinations of them as well as by glucuronidation and 
sulfation of phase I metabolites. Incubations with mixtures of pooled human liver microsomes and 
cytosols (pHLM and pHLC) confirmed that the main metabolic reactions in humans and rats might 
be identical. Furthermore, initial CYP activity screenings revealed that CYP1A2, CYP2C19, 
CYP2D6, and CYP3A4 were involved in hydroxylation, CYP2C19 and CYP2D6 in O-
demethylation, and CYP2C19, CYP2D6, and CYP3A4 in N-dealkylation. For SUSAs, GC-MS, 
LC-MSn, and LC-HR-MS/MS were applied to rat urine samples after 1 or 0.1 mg/kg BW doses, 
respectively. In contrast to the GC-MS SUSA, both LC-MS SUSAs were able to detect an intake of 
5-MeO-2-Me-ALCHT and 5-MeO-2-Me-DIPT via their metabolites following 1 mg/kg BW 
administrations and 5-MeO-2-Me-DALT following 0.1 mg/kg BW dosage.  
 
Keywords: new psychoactive substances; tryptamines; metabolism; cytochrome-P450; LC-MSn; 
LC-HR-MS/MS 
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Introduction 
 
New psychoactive substances (NPS) have become increasingly popular among drug users around 
the world.[1] As many of them are not regulated, these substances are marketed to avoid criminal 
prosecution for production, trading, drug possession, or consumption. NPS often mimic the effects 
of their traditional counterparts.[1] Several hundred substances are classified as NPS where research 
on the potential harm for consumers is limited. Synthetic cannabinoids, phenylethylamines, 
synthetic cathinones, and tryptamines were the most prevalent representatives of NPS during the 
last few years.[1] The biological effects associated with many psychoactive tryptamine derivatives 
are at least in part mediated by agonism at 5-HT1A and 5-HT2A receptors leading to hallucinogenic 
and stimulating effects.[2-7] The synthesis and mode of action for many synthetic tryptamines were 
described by Shulgin and Shulgin.[8] Examples of tryptamines described by them and subsequently 
appeared in case reports include 5-MeO-MIPT (5-methoxy-N-methyl-N-isopropyltryptamine)[9] and 
5-MeO-DIPT (5-methoxy-N,N-diisopropyltryptamine).[10-14] Other tryptamines, such as 5-MeO-
DALT (5-methoxy-N,N-diallyltryptamine),[15,16] originally not described by Shulgin and Shulgin in 
1997,[8] have also appeared on the market and were linked to intoxication cases. Shulgin and 
Shulgin[8] have also described the effects of tryptamines substituted on the 2-position of the indole 
ring such as 5-MeO-TMT (5-methoxy-2,N,N-trimethyltryptamine). From this perspective, it seems 
conceivable that other 2-methylated tryptamines might also appear on the drug market. In cases of 
intoxication with such substances, it is necessary to provide analytical detection methods, such as 
standard urine screening approaches (SUSAs)[17] in order to facilitate adequate support of the 
therapeutic strategy used for clinical treatment. As shown by Michely et al.,[18] tryptamines were 
mainly excreted as metabolites thus the targets for urine screening have to be elucidated by 
metabolism studies to include those in SUSAs. This work here is focused on the metabolism and 
the detectability of the three NPS 5-methoxy-2-methyl-N,N-diallyltryptamine (5-MeO-2-Me-
DALT), 5-methoxy-2-methyl-N-allyl-N-cyclohexyltryptamine (5-MeO-2-Me-ALCHT), and 5-
methoxy-2-methyl-N,N-diisopropyltryptamine (5-MeO-2-Me-DIPT), respectively.  
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Experimental 
 
Chemicals and reagents 
 
5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were available from previous 
studies and synthesized by Brandt et al.[19-21] Isocitrate, isocitrate dehydrogenase, and 3’-
phosphoadenosine-5’-phosphosulfate (PAPS) were received from Sigma-Aldrich (Taufkirchen, 
Germany), NADP+ from Biomol (Hamburg, Germany), and methanol (LC-MS grade), ammonium 
formate (analytical grade), formic acid (LC-MS grade), and acetonitrile (LC-MS grade) and all 
other chemicals or reagents (analytical grade) from VWR (Darmstadt, Germany). The baculovirus-
infected insect cell microsomes (supersomes) containing human cDNA-expressed cytochrome P450 
(CYP) enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 
(1 nmol/mL, each), or CYP2E1, CYP3A5 (2 nmol/mL, each), pooled human liver microsomes 
(pHLM, 20 mg microsomal protein/mL, 330 pmol total CYP/mg protein), pooled human liver 
cytosols (pHLC, 20 mg cytosolic protein/mL), UDP-glucuronyltransferase (UGT) reaction mix 
solution A (25 mM UDP-glucuronic acid), and UGT reaction mix solution B (250 mM Tris-HCl, 40 
mM MgCl2, and 0.125 mg/mL alamethicin) were obtained from Corning (Amsterdam, The 
Netherlands). After delivery, the enzyme preparations were thawed at 37°C, aliquoted, snap-frozen 
in liquid nitrogen, and stored at -80°C until use. 
 
Urine samples 
 
The compounds were orally administered in an aqueous suspension by gastric intubation to male 
Wistar rats (Charles Rivers, Sulzfeld) for toxicological diagnostic reasons.[18] Doses were 20 mg/kg 
body weight (BW) for metabolism studies (identification of metabolites), 1 mg/kg BW for 
toxicological analyses, and 0.1 mg/kg BW for estimation of the detectability of very low dosed 
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5 
 
applications, respectively. After administration, the rats were housed in metabolism cages for 24 h. 
Water was provided ad libidum and urine collected separately from feces. Before administration, 
blank urine samples were collected to evaluate the absence of interfering compounds. Urine 
samples were extracted, analyzed, and stored at -20°C immediately after collection. 
 
Sample preparation for identification of phase I and II metabolites by LC-HR-MS/MS 
 
As described elsewhere,[22] 100 µL urine were mixed with 500 µL acetonitrile, vortexed for 2 min 
and centrifuged for further 2 min at 10,000 g. Five hundred µL of the supernatant were transferred 
into a glass vial and evaporated at 70°C under a stream of nitrogen. The residue was dissolved in 50 
µL of a mixture (1:1; v/v) of eluents A (2 mM aqueous ammonium formate plus 0.1% formic acid, 
pH 3) and B (2 mM aqueous ammonium formate with acetonitrile:methanol, 50:50, v/v; 1% water 
plus 0.1% formic acid) and a 1-µL aliquot was injected onto the LC-HR-MS/MS system. 
 
Conditions for incubations for initial CYP activity screening studies 
 
According to Richter et al.,[23] final concentrations of 25 µM substrate were used. The microsomal 
incubations were performed for 30 min at 37°C, each containing one of the following enzymes at 
50 pmol/mL: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
CYP3A4, and CYP3A5. Further components in the final 50 µL incubation volume were phosphate 
buffer (90 mM, pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 1.6 U/mL isocitrate 
dehydrogenase, and 200 U/mL superoxide dismutase. According to the Gentest manual, phosphate 
buffer was replaced with 45 and 90 mM Tris buffer for incubation of CYP2A6 and CYP2C19. 
Reactions were initiated by addition of the respective test substrate and stopped by addition of 50 
µL ice-cold acetonitrile. The solution was then centrifuged for 5 min at 10,000 g, 70 µL of the 
supernatant were transferred to an autosampler vial, and 1 µL was injected onto the LC-HR-MS/MS 
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system. Blank and negative control samples were also prepared accordingly, whereby substrate or 
enzymes were replaced with buffer, respectively. 
 
Conditions for incubations with pHLM + pHLC  
 
As described by Richter et al.,[23] the in vitro drug metabolism studies using a mixture of pHLM 
and pHLC were done with final protein concentrations of 1 mg/mL each. After 10 min of 
preincubation at 37°C with 20 µL UGT reaction mix solution B, pHLM, pHLC, 90 mM phosphate 
buffer (pH 7.4), 2.5 mM Mg2+, 2.5 mM isocitrate, 0.6 mM NADP+, 0.8 U/mL isocitrate 
dehydrogenase, 100 U/mL superoxide dismutase, 10 µL UGT reaction mix A, and 40 µM aqueous 
PAPS were added. All given concentrations are final concentrations. The reaction was initiated by 
adding substrate at 25 µM (100 µL final volume) and stopped after 30 min incubation time with 50 
µL ice-cold acetonitrile. The samples were centrifuged for 2 min at 10,000 g, 100 µL of the 
supernatant transferred into an autosampler vial, and 1 µL injected onto the LC-HR-MS/MS 
system. A blank and a negative control sample were also prepared, whereby substrate or enzyme 
was replaced with buffer, respectively. 
 
LC-HR-MS/MS apparatus for identification of phase I and II metabolites in urine and 
incubations 
 
The prepared samples were analyzed using a ThermoFisher Scientific (TF, Dreieich, Germany) 
Dionex UltiMate 3000 RS LC system, consisting of a degasser, a quaternary pump, and an UltiMate 
autosampler and coupled to a TF Q-Exactive Plus system equipped with heated electrospray 
ionization (HESI)-II source. The instrument was used in positive ionization mode. According to the 
manufacturer’s manual, mass calibration was done before analysis using external mass calibration. 
LC and MS settings were according to published procedures.[23,24] The gradient elution was 
performed on a TF Accucore PhenylHexyl column (100 x 2.1 mm, 2.6 µm). Chromatographic 
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separation was performed at 40°C supplied by an analytical column heater (Dionex UltiMate 3000). 
The gradient was programmed as follows: 0-1 min 99% A, 1-10 min to 1% A, 10-11.5 min hold 1% 
A, and 11.5-13.5 min hold 99% A. The flow rate was set to 500 µL/min for 10 min and 800 µL/min 
from 10 to 13.5 min. The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units 
(AU); auxiliary gas, 10 AU; spray voltage, 3.00 kV; heater temperature, 320°C; ion transfer 
capillary temperature, 320°C; and S-lens RF level, 60.0. Mass spectrometry analyses were 
performed using full-scan (FS) data and a subsequent data dependent acquisition (DDA) mode with 
an inclusion list of the m/z values of 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, 5-MeO-2-Me-
DIPT and their potential metabolites. Additional DDA without inclusion list was performed to 
detect unexpected metabolites. The settings for FS acquisition were as follows: resolution, 35,000; 
microscans, 1; automatic gain control (AGC) target, 1e6; maximum injection time (IT), 120 ms; 
and scan range, m/z 130-1000; loop count, 5; dynamic exclusion, 1 s. The settings for DDA mode 
were as follows: resolution, 17,500; microscans, 1; AGC target, 2e5; maximum IT, 250 ms; 
isolation window, 1.0 m/z, HCD with stepped normalized collision energy (NCE), 17.5, 35, and 
52.5%; spectrum data type, profile; underfill ratio, 0.5% (corresponding to a signal with an 
abundance of 4e3); option exclude isotopes, enabled. Software for data evaluation was Thermo 
Fisher Xcalibur 2.2 SP1.48. 
 
Standard urine screening approaches (SUSA) 
 
The SUSAs were performed as described previously: GC-MS SUSA,[17,25] LC-MSn SUSA,[26,27] and 
LC-HR-MS/MS SUSA.[26,28] 
 
 
Results and discussion 
 
Identification of phase I and II metabolites via LC-HR-MS/MS  
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Mass spectral interpretations were based on general fragmentation rules[29] and by comparison with 
the spectra of the parent compounds. All phase I and II metabolites tentatively identified based on 
their MS2 spectra are depicted in Figures S1-S6 in Supporting Information (SI). Additionally, the 
spectra contain the supposed chemical structures, the accurate measured masses, the molecular 
formulae, and the corresponding mass error values in parts per million (ppm). 
 
Proposed fragmentation patterns for identification of phase I metabolites via LC-HR-MS/MS 
 
In general, all metabolites were identified based on their m/z values of the protonated molecule 
(PM), the calculated molecular formulae, and the fragmentation patterns compared to those of the 
parent compounds. They were sorted by PM and with abbreviations for the corresponding 
compound (5-MeO-2-Me-DALT, D; 5-MeO-2-Me-ALCHT, A; and 5-MeO-2-Me-DIPT, P). Due to 
the large number of metabolites detected in this study, only representative examples have been 
chosen to illustrate the fragmentation patterns. Following the suggestion described by Michely et 
al.,[18] the chemical structures were divided into three sections to allow a convenient description of 
fragmentation patterns and positions of metabolic reactions. Section 1 represents the aromatic ring 
system, section 2 the ethyl spacer, and section 3 the variabl  amine part of the molecule. As 
expected, the fragment ions formed by section 1 and 2 were the same for 5-MeO-2-Me-DALT, 5-
MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT. All masses in the following sections are the 
calculated (exact) masses. 
 
5-MeO-2-Me-DALT 
 
As shown in Figure S1 (see SI), 24 phase I metabolites of 5-MeO-2-Me-DALT could be identified. 
5-MeO-2-Me-DALT (D1 in Figure S1; PM at m/z 285.1961, C18H25ON2+) showed a fragmentation 
comparable to DALT and 5-MeO-DALT[18] and for most of the detected metabolites. The fragment 
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9 
 
ions of m/z 188.1070 (C12H14ON+) and 110.0964 (C7H12N+) represented typical α-cleavage of the 
tryptamine structure forming the characteristic fragment ions of sections 1 plus 2 (m/z 188.1070, 
C12H14ON+) and section 3 (m/z 110.0964, C7H12N+). The fragment ion of m/z 173.0835 
(C11H11ON●+) resulted by a loss of a methyl radical of the methoxy group. For metabolite 
identification, the representative MS2 fragment ions for section 3 were used in most cases. 
Unmodified section 3 led to a fragment ion of m/z 110.0964 (C7H12N+), which suggested that the 
expected modification took place in sections 1 or 2. Modified section 3 led to fragment ions of m/z 
70.0651 (C4H8N+, N-deallylated) as shown e.g. in the MS2 spectrum of N-deallyl-5-MeO-2-Me-
DALT (D5, PM at m/z 245.1648, C15H21ON2+). As expected, the fragment ions of unchanged 
sections 1 and 2 (m/z 173.0835 and 188.1070) were also present. After O-demethylation, 
corresponding fragment ions of m/z 159.0679 (C10H9ON+) and 174.0913 (C11H12ON+), shown e.g. 
in the MS2 spectrum of O-demethyl-5-MeO-2-Me-DALT (D11, PM at m/z 271.1805, C17H23ON2+), 
were detected, which was consistent with the detection of m/z 110.0964 (C7H12N+). Furthermore, 
five isomers with the PM of m/z 301.1911, C18H25 O2N2+) could be observed and predicted to 
represent hydroxylated metabolites (D16-D20). Isomers 1-4 (D16-D19) showed fragment ions of 
m/z 110.0964 (C7H12N+) indicating that the hydroxylation took place at sections 1 or 2. In the MS2 
spectrum of hydroxy-alkyl isomer 1 (D16), no specific shifts could be detected for the fragment 
ions (e.g. 188.1070 to 204.1019, +15.9949, +O) associated with sections 1 and 2 or any loss of 
water as in the MS2 spectrum of hydroxy-alkyl isomer 2, which could indicate hydroxylation 
probably at the 2-methyl group of section 1. The fragment ions of m/z 176.0706 (C10H10O2N+) and 
178.0863 (C10H12O2N+) represented a hydroxylated methyl group in section 1 with the positive 
charge at the carbon or at the nitrogen atom, respectively. In contrast, the MS2 spectra of the 
hydroxy-aryl isomers 1 and 2 (D17 and D18) showed typical shifts of +15.9949 u (+O) of the 
fragment ions of sections 1 and 2, thus, resulting in the fragment ions of m/z 189.0784 
(C11H11O2N+) and 204.1019 (C12H14O2N+). Furthermore, there were no fragment ions associated 
with a loss of water in these two spectra and thus the two isomers were predicted to be aryl 
hydroxylated metabolites (D17 and D18). In contrast, the MS2 spectrum of hydroxy-alkyl isomer 2 
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10 
 
(D19) showed such a loss of water (-18.0106 u, H2O), typically observed with alkyl hydroxy 
groups, and therefore resulting in m/z 186.0913 (C12H12ON+), which suggested that hydroxylation 
occurred in the ethylamine side chain in section 2. The MS2 spectrum of isomer 5 (D20) showed 
neither presence of the fragment ion of unchanged section 3 (m/z 110.0964, (C7H12N+), nor any 
typical shifts of this fragment ion. However, the fragment ions of unchanged sections 1 and 2 were 
detected and therefore the metabolite was inconsistent with a hydroxylated species. The presence of 
an N-oxide metabolite seemed likely as D20 had a longer retention time (5.0 min) than the parent 
compound (4.8 min) on the reversed phase column. This was observed for all N-oxides for which 
reference standards were available.[30] 
 
5-MeO-2-Me-ALCHT and 5-MeO-2-Me-DIPT 
 
According to Figures S3 and S5 (see SI), 24 phase I metabolites could be identified for 5-MeO-2-
Me-ALCHT and 20 phase I metabolites for 5-MeO-2-Me-DIPT, respectively. As already 
mentioned above, the fragmentation patterns of the two parent compounds were comparable to 
those of 5-MeO-2-Me-DALT. The α-cleavages of 5-MeO-2-Me-ALCHT (A1 in Figure S3; PM at 
m/z 327.2431, C21H31ON2+) and 5-MeO-2-Me-DIPT (P1 in Figure S5; PM at m/z 289.2274, 
C18H29ON2+) formed the fragment ions of m/z 188.1070 (C12H14ON+) representing sections 1 and 2 
and m/z 152.1434 (C10H18N+) and m/z 114.1277 (C7H16N+), respectively, representing the iminium 
ion of section 3. In contrast to 5-MeO-2-Me-DALT, for both compounds a further breakdown of 
section 3 could be detected, forming the fragment ions of m/z 70.0651 (C4H8N+) after loss of the 
cyclohexyl group and m/z 72.0807 (C4H10N+) after loss of one isopropyl group. The metabolite 
formed after N,N-bis-dealkylation (N,N-bis-deallyl, D2; N-deallyl-N-decyclohexyl, A2; and N,N-
bis-deisopropyl metabolite, P2) and the further deaminated and oxidized carboxy metabolite (D3, 
A3, and P3) were identical for all three compounds, representing the conserved 2-methyltryptamine 
structure. Furthermore, all metabolites formed after N-deallylation of 5-MeO-2-Me-DALT (D4-
D10) and N-decyclohexylation of 5-MeO-2-Me-ALCHT (A4-A9) were identical for both 
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11 
 
compounds, except for D7 which was only found after N-deallylation and oxidation of 5-MeO-2-
Me-DALT. 
 
Proposed fragmentation patterns for identification of phase II metabolites via LC-HR-
MS/MS 
 
5-MeO-2-Me-DALT 
 
As shown in Figure S2 (see SI), all 12 identified phase II metabolites were conjugated at the indole 
part. The conjugates showed the same fragment ions as the underlying phase I metabolites after a 
characteristic elimination of glucuronic acid (-176.0321 u) of the glucuronides and of sulfuric acid 
(-79.9568 u) of the sulfates. The fragment ions of m/z 240.0325 (C10H10O4NS+), 254.0482 
(C11H12O4NS+), and 284.0587 (C12H14O5NS+) formed after sulfation and the fragment ions of m/z 
336.1078 (C16H18O7N+), 350.1234 (C17H20O7N+), 366.1183 (C17H20O8N+), and 380.1340 
(C18H22O8N+) after glucuronidation at the ethylindole part (section 1 and 2) after O-demethylation 
or aryl-hydroxylation, respectively. 
 
5-MeO-2-Me-ALCHT and 5-MeO-2-Me-DIPT 
 
As shown in Figures S4 and S6 (see SI), 14 phase II metabolites of 5-MeO-2-Me-ALCHT and 11 of 
5-MeO-2-Me-DIPT could be identified. As already described for 5-MeO-2-Me-DALT, all 
glucuronides and sulfates eliminated glucuronic acid (-176.0321 u) or sulfuric acid (-79.9568 u). In 
addition, conjugation always took place at the ethylindole part after O-demethylation or aryl-
hydroxylation, forming the same fragment ions of the conjugated partial structure. As both 
compounds have some common phase I metabolites following N-dealkylation, the resulting phase II 
metabolites after further conjugation were consequently also identical (D6S, D8S, D4G, D6G, and 
D8G2 for 5-MeO-2-Me-DALT; A6S, A9S, A4G, A6G, and A9G for 5-MeO-2-Me-ALCHT). 
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Proposed metabolic pathways 
 
Based on the identified metabolites, the metabolic pathways for 5-MeO-2-Me-DALT, 5-MeO-2-
Me-ALCHT, and 5-MeO-2-Me-DIPT were proposed and depicted in Figures 1-3. The numbering is 
given in Figures S1, S3, and S5 (see SI). As expected, the main metabolic reactions observed for all 
three test drugs were comparable. 
 
5-MeO-2-Me-DALT 
 
Four different hydroxy isomers could be detected. Two isomers of hydroxy-aryl (D17 and D18) 
were formed by hydroxylation at the indole part. Hydroxy-alkyl isomer 1 (D16) led to further 
oxidation and/or hydroxylation steps in section 1 (D15, D21, D22, and D23). Hydroxylation at 
section 2, forming hydroxy-alkyl isomer 2 (D19), was probably the preliminary step for the 
formation of two N-deallyl-oxo isomers 1 and 2 (D7 and D8). Moreover, N-oxidation (D20) alone 
and in combination with aryl hydroxylation (D24) was identified. The intermediate mono-hydroxy 
metabolite that led to the bis-hydroxylated product (both section 3; D25) was not detected. Initial 
O-demethylation (D11) and further oxidation led to O-demethyl-hydroxy-alkyl isomer 1 and 2 (D12 
and D13) and O-demethyl-N-oxide (D14). Combination of O-demethylation and N-deallylation led 
to O-demethyl-N-deallyl metabolite (D4), following hydroxylation to O-demethyl-N-deallyl-
hydroxy-alkyl (D6). After N-deallylation and further hydroxylation, two N-deallyl-hydroxy 
metabolites (D9, hydroxy-aryl and D10, hydroxy-alkyl) could be found. Finally, when D5 was 
further deallylated, a N,N-bis-deallyl metabolite (D2) was formed, that might have been deaminated 
and carboxylated to give N,N-bis-deallyl-deamino carboxylic acid (D3). Glucuronidation and 
sulfation could be observed for O-demethyl-N-deallyl (D4), O-demethyl-N-deallyl-hydroxy-alkyl 
(D6), N-deallyl-hydroxy-aryl (D9), O-demethyl (D11), and hydroxy-aryl isomer 2 (D18) 
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metabolites. For O-demethyl-hydroxy-alkyl isomer 2 (D13) and hydroxy-aryl isomer 1 (D17), only 
the glucuronidation species were detected.  
 
5-MeO-2-Me-ALCHT 
 
The metabolic pathways were similar to those observed for 5-MeO-2-Me-DALT including N-
oxidation (A23), aliphatic (A20 and A21) and aromatic (A22) hydroxylation. However, aliphatic 
hydroxylations did not affect section 2 but the 2-methyl substituent in section 1 and the cyclohexyl 
ring in section 3 instead. Combination of both hydroxylation types (aromatic and aliphatic) showed 
the bis-hydroxy metabolite (A25). An intermediate biotransformation step (aliphatic hydroxylation 
at the 2-methyl substituent) was originally considered, but this could not be identified, possibly due 
to fast oxidation to the carboxylic acid (A24). In contrast to 5-MeO-2-Me-DALT and 5-MeO-2-Me-
DIPT reflecting a symmetrical N,N-dialkylation pattern, 5-MeO-2-Me-ALCHT represents an 
asymmetrically substituted amine. In consequence, besides the comparable O-demethylation (A17) 
with further cyclohexyl hydroxylation (A18 and A19) and N-deallylation (A11), N-
decyclohexylation (A5) was found to be an important metabolic step as well. N-decyclohexylation 
of 5-MeO-2-Me-ALCHT produced the same metabolite that resulted from N-deallylation of 5-
MeO-2-Me-DALT. Similarly, additional transformations included hydroxylations (A8 and A9), 
oxidation to amide structure (A7), O-demethylation (A4), combinations of both (A6), and further N-
deallylation (A2), followed by oxidation to the corresponding carboxylic acid (A3). Retention times 
and MS2 spectra of these metabolites were the same for 5-MeO-2-Me-DALT and -ALCHT. 
However, the alpha-position in metabolites A7 and D8 is not the probable position due to fact that 
the intermediate should be an unstable hemiaminal. The N-deallylated metabolite (A11) could be 
further metabolized by hydroxylation (A15 and A16), oxidation to an aldehyde (D14), O-
demethylation (A10), and combination of O-demethylation with hydroxylation (A12 and A13). 
Glucuronidation and sulfation were found for O-demethyl-N-decyclohexyl-hydroxy-alkyl (A6), N-
decyclohexyl (A8), O-demethyl-N-deallyl (A10), O-demethyl-N-deallyl-hydroxy-cyclohexyl (A12), 
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O-demethyl (A17), and O-demethyl-hydroxy-cyclohexyl (A18) metabolites, whereas O-demethyl-
N-decyclohexyl (A4) was only found as glucuronide. Two glucuronide isomers (A8G1 and A8G2) 
were detected for the N-decyclohexyl-hydroxy-aryl metabolite (A8). 
 
5-MeO-2-Me-DIPT 
 
As expected, most 5-MeO-2-Me-DIPT metabolites were found to be equivalent to those described 
above, such as aliphatic (P15 and P18) and aromatic (P16 and P17) hydroxylations, combination of 
aliphatic and aromatic hydroxylation (P21), oxidation to an aldehyde (P14), and the corresponding 
carboxylic acid (P19), O-demethylation (P11), and N-deisopropylation (P5). The aldehyde 
metabolite (P14) could be further oxidized forming hydroxy-alkyl-oxo metabolite (P20). 
Furthermore, N,N-bis-deisopropylation (P2) and deamination to the corresponding carboxylic acid 
(P3) leading to the same metabolites as already seen for the DALT (D2 and D3) and ALCHT (A2 
and A3) analogue. Combinations of N-deisopropylation with hydroxylations (P9 and P10) and O-
demethylation (P6) as well as combinations of O-demethylation with hydroxylations (P12 and P13), 
and O-demethylation with N-deisopropylation (P4) were discovered. N-Deisopropylation in 
combination with oxidation to two oxo isomers (P7 and P8) could also be found as for the DALT 
analogue (D7 and D8). Glucuronidation and sulfation could be observed for O-demethyl-N-
deisopropyl (P4) and O-demethyl (P11) metabolites. For O-demethyl-N-deisopropyl-hydroxy-alkyl 
(P6), N-deisopropyl-hydroxy-aryl (P9), O-demethyl-hydroxy-alkyl isomer 2 (P13), hydroxy-aryl 
isomer 1 and 2 (P16 and P17), and aryl-alkyl-bis-hydroxy (P21) metabolites, only glucuronides 
were found. Two glucuronide isomers (P9G1 and P9G2) were detected for the N-deisopropyl-
hydroxy-aryl metabolite (P9). 
 
Comparison to published 5-MeO-DALT and 5-MeO-DIPT metabolism studies 
 
5-MeO-2-Me-DALT 
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Michely et al.,[18] described the metabolism of 5-MeO-DALT in rats. The main metabolic reactions 
(O-demethylation, hydroxylations, and N-deallylation) were similar for both compounds. However, 
some metabolites, especially those modified at the 2-methyl group could only be found for 5-MeO-
2-Me-DALT. Compared to 5-MeO-DALT, no bis- or tris-hydroxylations and no ring-rearranged 
metabolite could be found for the 2-methyl derivative probably due to the substitution of the 2 
position of the indole ring which could lead to a steric hindrance for the rearrangement. In addition, 
N,N-bis-deallylation followed by oxidative deamination and N-oxidation could only be detected for 
5-MeO-2-Me-DALT. 
 
5-MeO-2-Me-DIPT 
 
Narimatsu et al.,[31-33] described, besides CYP kinetic studies, only the presence of a O-
demethylated, a N-deisopropylated, and a mono-hydroxylated metabolite in rat and human liver 
microsomes, which all were also found in our study for 5-MeO-2-Me-DIPT. 
 
Initial CYP activity screening studies 
 
The ten most abundant human hepatic CYPs were incubated as described above to provide a 
qualitative description of metabolizing isoenzymes. As shown in Table 1, the involved isoenzymes 
were the same for the three NPS. O-Demethylation was catalyzed by CYP2C19 and CYP2D6, N-
deallylation, or N-deisopropylation by CYP2C19, CYP2D6, and CYP3A4, and hydroxylations by 
CYP1A2, CYP2C19, CYP2D6, and CYP3A4. Additionally, the N-decyclohexylation of 5-MeO-2-
Me-ALCHT was catalyzed by CYP2C9, CYP2C19, and CYP3A4. 
 
Incubations with pHLM and pHLC 
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Due to the lack of authentic human urine samples, in vitro testing was performed to evaluate the 
transferability of rat metabolism results to humans. The combination of rat urine studies and the 
incubation of pHLM and/or pHLC with the corresponding cofactors is a common technique that 
produced reliable results and data for detection methods in human urine as shown in previous 
studies.[23,34-37] However, it should be kept in mind, that the comparison of in vitro and in vivo 
models could be challenging due to sampling time of urine (24 h), time, amount, and route of 
application, the used incubation conditions, and/or genetic variations. 
 
5-MeO-2-Me-DALT 
 
As summarized in Table 2, 22 out of 24 identified phase I metabolites of 5-MeO-2-Me-DALT were 
detected in rat urine, 14 could be confirmed in the in vitro approach. In addition, two hydroxy-alkyl 
metabolites (D16 and D19) were only detected in the in vitro model. This was probably based on 
the 24 hours urine collection period and consequently further metabolism steps to the corresponding 
oxo or carboxy metabolites occurred in rat. D4, D6, D9, D11, D13, D17, and D18 were found as 
glucuronides, and D4, D6, D9, D11, and D18 as sulfates in vivo. D11, D17, and D18 were found as 
glucuronides and D18 as sulfate in vitro. These differences could have been based on the incubation 
time and lower formation of the corresponding phase I metabolites, especially in cases where 
multiple metabolic reaction steps were needed. 
 
5-MeO-2-Me-ALCHT 
 
As shown in Table 3, 17 out of 24 identified in vivo phase I metabolites of 5-MeO-2-Me-ALCHT 
could be recovered from the in vitro model. Eight glucuronides and six sulfates were detected in rat 
urine and one glucuronide under in vitro conditions. The reasons for these differences were 
considered comparable to those mentioned above. In comparison to 5-MeO-2-Me-DALT, no 
additional metabolites could be found in the in vitro model when compared to the in vivo approach. 
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5-MeO-2-Me-DIPT 
 
According to Table 4, 15 out of 20 phase I metabolites identified in vivo could also be found in the 
in vitro model. Nine glucuronides and two sulfates were identified in vivo, whereas two 
glucuronides were detected in vitro. 
 
Toxicological detection by standard urine screening approaches (SUSAs) 
 
So far, no data about dosages or potency of the compounds are available. Therefore, the tested 
dosages for 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were estimated 
based on those described for other tryptamine-derived NPS and were set to 1 mg/kg BW and 0.1 
mg/kg BW. Michely et al.[18] showed that such dosages were at or below common users doses of 
DALT and 5-MeO-DALT. The fact that the 0.1 mg/kg BW dosage was not detectable (except of 5-
MeO-2-Me-DALT) could lead to a false negative result e.g. in context of forensic issues. 
 
 
 
GC-MS SUSA 
 
Unfortunately, the three compounds and/or their metabolites could not be detected in rat urine after 
low dosages probably due to low concentration or instabilities caused by the sample preparation. 
However, after high dose administration, some metabolites were detected, indicating that the 
compounds might be detectable in a case of acute overdose. 
 
LC-MSn SUSA 
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A list of all detected metabolites is given in Tables 5 and 6. 5-MeO-2-Me-DALT was detectable via 
its metabolites after both low dose administrations. For 5-MeO-2-Me-ALCHT as well as 5-MeO-2-
Me-DIPT, only metabolites were detectable after 1 mg/kg BW dosages, but not after the lower 0.1 
mg/kg BW dosages. 
 
LC-HR-MS/MS SUSA 
 
As summarized in Table 7, metabolites of 5-MeO-2-Me-DALT and 5-MeO-2-Me-DIPT could be 
identified with the accurate PM and a HR-MS/MS spectrum (identification, I) after 1 mg/kg BW 
dose administrations. In addition, metabolites could be identified after the lower 0.1 mg/kg BW 
dosage for 5-MeO-2-Me-DALT. For 5-MeO-2-Me-ALCHT, only detection (D) of the accurate PM 
without the corresponding HR-MS/MS spectrum was possible. A second run with an inclusion list 
on the masses of described metabolites would be necessary to confirm an intake of 5-MeO-2-Me-
ALCHT. The parent compounds were not identified, nor have they been detected in any of the urine 
samples. Exemplified for 5-MeO-2-Me-DALT, Figure 4 shows a reconstituted ion chromatogram 
of the 1 mg/kg BW dosage rat urine sample with various detected metabolites. 
 
Conclusions 
 
5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT were extensively 
metabolized in rats. In vitro metabolism studies with pHLM plus pHLC showed similar results, 
which indicated that the described metabolites should also be detectable in human urine samples. 
CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were identified to be involved in the 
biotransformation described in this study. An intake of an estimated users’ dose of 1 mg/kg BW 
was detectable via the metabolites by both LC-MS SUSAs for 5-MeO-2-Me-DALT and 5-MeO-2-
Me-DIPT. For 5-MeO-2-Me-ALCHT, a separate run using an inclusion list on the targets of interest 
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would be necessary for detection. In addition, 5-MeO-2-Me-DALT metabolites were also 
detectable after the lower 0.1 mg/kg BW dosage by both LC-MS SUSAs. 
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Table 1 CYP isoenzymes involved in metabolic pathways of 5-MeO-2-Me-DALT, 5-MeO-2-Me-
ALCHT, and 5-MeO-2-Me-DIPT 
Pathway CYP 
1A2 
CYP 
2A6 
CYP 
2B6 
CYP 
2C8 
CYP 
2C9 
CYP 
2C19 
CYP 
2D6 
CYP 
2E1 
CYP 
3A4 
CYP 
3A5 
5-MeO-2-Me-DALT 
O-Demethylation      + +    
N-Deallylation      + +  +  
Hydroxylations +     + +  +  
5-MeO-2-Me-ALCHT 
O-Demethylation      + +    
N-Deallylation      + +  +  
N-Decyclohexylation     + +   +  
Hydroxylations +     + +  +  
5-MeO-2-Me-DIPT 
O-Demethylation      + +    
N-Deisopropylation +     + +  +  
Hydroxylations +     + +  +  
 
 
Table 2 Appearance of 5-MeO-2-Me-DALT phase I and II metabolites in rat urine and in 
pHLM/HLC mix; G = glucuronide, S = sulfate; numbering according to Figure S1 (see SI). 
Metabolite Rat urine pHLM/HLC Phase I Phase II Phase I Phase II 
D2 +    
D3 +    
D4 + + G/S +  
D5 +  +  
D6 + + G/S +  
D7 +    
D8 +    
D9 + + G/S +  
D10 +  +  
D11 + + G/S + + G 
D12 +  +  
D13 + + G +  
D14 +    
D15 +  +  
D16   +  
D17 + + G  + G 
D18 + + G/S + + G/S 
D19   +  
D20 +  +  
D21 +  +  
D22 +  +  
D23 +    
D24 +    
D25 +  +  
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Table 3 Appearance of 5-MeO-2-Me-ALCHT phase I and II metabolites in rat urine and in 
pHLM/HLC mix; G = glucuronide, G1/G2 = glucuronide isomer 1 and 2, S = sulfate; numbering 
according to Figure S3 (see SI). 
Metabolite Rat urine pHLM/HLC Phase I Phase II Phase I Phase II 
A2 +    
A3 +    
A4 + + G +  
A5 +  +  
A6 + + G/S +  
A7 +    
A8 + + G1/G2/S +  
A9 +  +  
A10 + + G/S +  
A11 +  +  
A12 + + G/S   
A13 +  +  
A14 +    
A15 +    
A16 +  +  
A17 + + G/S + + G 
A18 + + G/S +  
A19 +  +  
A20 +  +  
A21 +  +  
A22 +  +  
A23 +  +  
A24 +    
A25 +  +  
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Table 4 Appearance of 5-MeO-2-Me-DIPT phase I and II metabolites in rat urine and in 
pHLM/HLC mix; G = glucuronide, G1/G2 = glucuronide isomer 1 and 2, S = sulfate; numbering 
according to Figure S5 (see SI). 
Metabolite Rat urine pHLM/HLC Phase I Phase II Phase I Phase II 
P2 +    
P3 +    
P4 + + G/S +  
P5 +  +  
P6 + + G   
P7 +    
P8 +    
P9 + + G1/G2 +  
P10 +  +  
P11 + + G/S + + G 
P12 +  +  
P13 + + G +  
P14 +  +  
P15 +  +  
P16 + + G + + G 
P17 + + G +  
P18 +  +  
P19 +  +  
P20 +  +  
P21 + + G +  
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Table 5 Metabolites of 5-MeO-2-Me-DALT, m/z values of protonated molecule, characteristic MS2 
and MS3 fragment ions, and retention time (RT) detected by LC-MSn SUSA in both low dose urines 
(1 mg/kg BW and 0.1 mg/kg BW). The numbers correspond to those shown in Figures S1 and S2 
(see SI). 
No. Target for SUSA Protonated 
molecule, 
m/z 
MS2 fragment ions, m/z, and 
relative intensity, % 
MS3 fragment ions, m/z, and 
relative intensity, %, on the ion 
given in bold 
RT, min 
D4 5-MeO-2-Me-DALT-M 
(O-demethyl-N-deallyl-) 
231 174 (100) 174: 146 (100), 133 (23), 131 (8) 4.3 
D11 5-MeO-2-Me-DALT-M 
(O-demethyl-) 
271 174 (100), 110 (4) 174: 146 (100), 133 (10), 131 (10) 6.2 
D11 
G 
5-MeO-2-Me-DALT-M 
(O-demethyl-) 
glucuronide 
447 350 (100), 271 (74), 174 (79) 350: 174 (100), 253 (26), 146 (2) 4.5 
D13 
G 
5-MeO-2-Me-DALT-M 
(O-demethyl-HO-allyl-aryl-) 
glucuronide 
463 366 (100), 190 (6) 366: 190 (100), 172 (4) 4.6 
D17 
G 
 
5-MeO-2-Me-DALT-M 
(O-demethyl-HO-allyl-aryl-) 
glucuronide 
477 380 (100), 204 (18), 301 (7) 380: 204 (100), 172 (7) 5.0 
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Table 6 Metabolites of 5-MeO-2-Me-ALCHT and 5-MeO-2-Me-DIPT, m/z values of protonated 
molecule, characteristic MS2 and MS3 fragment ions, and retention time (RT) detected by LC-MSn 
SUSA in low dose urine (1 mg/kg BW). The numbers correspond to those shown in Figures S3-S6 
(see SI). 
No. Target for SUSA Protonated 
molecule, 
m/z 
MS2 fragment ions, m/z, and 
relative intensity, % 
MS3 fragment ions, m/z, and 
relative intensity, %, on the ion 
given in bold 
RT, min 
A10 
G 
5-MeO-2-Me-ALCHT-M 
(O-demethyl-N-deallyl-) 
glucuronide 
449 174 (100), 273 (99),350 (20), 159 (13) 174: 146 (100) 
273: 174 (100) 
6.1 
A17 
G 
5-MeO-2-Me-ALCHT-M 
(O-demethyl-) 
glucuronide 
489 350 (100), 313 (85), 174 (84), 152 (3) 350: 174 (100) 7.6 
P11 5-MeO-2-Me-DIPT-M 
(O-demethyl-) 
275 174 (100), 114 (4) 114: 72 (100) 
174: 146 (100), 131 (13) 133 (9) 
6.0 
P20 5-MeO-2-Me-DIPT-M 
(HO-alkyl-oxo-) 
319 218 (100), 114 (6) 218: 190 (100), 186 (98),172 
(75),158 (55) 
6.6 
P21 5-MeO-2-Me-DIPT-M 
(HO-alkyl-HO-aryl-) 
321 220 (100), 205 (3), 114 (1) 220: 172 (100), 186 (98),190 (85), 
160 (68),174 (27) 
9.2 
P11 
G 
5-MeO-2-Me-DIPT-M 
(O-demethyl-) 
glucuronide 
451 350 (100), 174 (68), 275 (38) 174: 146 (100), 131 (11),133 (5) 4.3 
P13 
G 
 
5-MeO-2-Me-DIPT-M 
(O-demethyl-HO-alkyl-) 
glucuronide 
467 366 (100), 190 (76) 190: 134 (100) 
366: 190 (100), 172 (4) 
4.2 
P16 
G 
5-MeO-2-Me-DIPT-M 
(HO-aryl-) 
glucuronide isomer 1 
481 380 (100), 204 (11) 204: 172 (100), 204 (5) 4.6 
P17 
G 
5-MeO-2-Me-DIPT-M 
(HO-aryl-) 
glucuronide isomer 2 
481 380 (100), 204 (30) 204: 173 (100), 172 (82), 163 (54), 
204 (16) 
5.4 
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Table 7 Metabolites of 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT, 
calculated exact mass of the protonated molecule, and retention time (RT) detected by LC-HR-
MS/MS SUSA in rat urine (1 mg/kg body weight (BW) or 0.1 mg/kg BW). D = detection of 
protonated molecule in MS1, I = identification via MS1 and MS2; the numbers correspond to those 
shown in Figures S1-S6 (see SI). 
No. Target for SUSA Calculated exact masses 
of protonated molecule, 
m/z 
1 mg/kg BW dose 0.1 mg/kg BW dose RT, 
min 
D4 5-MeO-2-Me-DALT-M 
(O-demethyl-N-deallyl-) 
231.1492 I I 3.0 
D6 5-MeO-2-Me-DALT-M 
(O-demethyl-N-deallyl-HO-alkyl-) 
247.1441 D D 2.6 
D11 5-MeO-2-Me-DALT-M 
(O-demethyl-) 
271.1805 I I 3.6 
D13 5-MeO-2-Me-DALT-M 
(O-demethyl-HO-alkyl-) isomer 2 
287.1754 I  3.3 
D17 5-MeO-2-Me-DALT-M 
(HO-aryl-) isomer 1 
301.1911 D D 3.8 
D18 5-MeO-2-Me-DALT-M 
(HO-aryl-) isomer 2 
301.1911 I  4.0 
D21 5-MeO-2-Me-DALT-M 
(HOOC-) 
315.1703 D  3.7 
D11 
S 
5-MeO-2-Me-DALT-M 
(O-demethyl-) sulfate 
351.1373 D  3.8 
D4 
G 
5-MeO-2-Me-DALT-M 
(O-demethyl-N-deallyl-) glucuronide 
407.1813 D D 2.7 
D11 
G 
5-MeO-2-Me-DALT-M 
(O-demethyl-) glucuronide 
447.2123 I I 3.3 
D17 
G 
5-MeO-2-Me-DALT-M 
(HO-aryl-) glucuronide 
477.2231 D D 3.4 
A17 5-MeO-2-Me-ALCHT-M 
(O-demethyl-) 
313.2274 D  4.9 
A8 
G1 
5-MeO-2-Me-ALCHT-M 
(N-decyclohexyl-HO-aryl-) 
glucuronide isomer 1 
437.2282 D  3.1 
A10 
G 
5-MeO-2-Me-ALCHT-M 
(O-demethyl-N-deallyl-) glucuronide 
449.2282 D  3.8 
A17 
G 
5-MeO-2-Me-ALCHT-M 
(O-demethyl-) glucuronide 
489.2595 D  4.3 
P4 5-MeO-2-Me-DIPT-M 
(O-demethyl-N-deisopropyl-) 
233.1648 I  3.1 
P11 5-MeO-2-Me-DIPT-M 
(O-demethyl-) 
275.2118 I  3.7 
P12 5-MeO-2-Me-DIPT-M 
(O-demethyl-HO-alkyl-) isomer 1 
291.2067 I  2.8 
P20 5-MeO-2-Me-DIPT-M 
(HOOC-) 
319.2016 D  3.9 
P4 5-MeO-2-Me-DIPT-M 409.1969 D  2.8 
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G (O-demethyl-N-deisopropyl-) 
glucuronide 
P11 
G 
5-MeO-2-Me-DIPT-M 
(O-demethyl-) glucuronide 
451.2439 D  3.2 
P13 
G 
5-MeO-2-Me-DIPT-M 
(O-demethyl-HO-alkyl-) glucuronide 
467.2389 D  3.2 
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Legends to Figures 
 
Figure 1 Proposed metabolic pathways of 5-MeO-2-Me-DALT. Phase II metabolites: glucuronides 
(G), and sulfates (S). Structures in brackets represent proposed (but not detected) intermediates; 
numbering according to Figure S1 (see SI). 
 
Figure 2 Proposed metabolic pathways of 5-MeO-2-Me-ALCHT. Phase II metabolites: 
glucuronides (G), and sulfates (S). Structures in brackets represent proposed (but not detected) 
intermediates; numbering according to Figure S3 (see SI). 
 
Figure 3 Proposed metabolic pathways of 5-MeO-2-Me-DIPT. Phase II metabolites: glucuronides 
(G), and sulfates (S). Structures in brackets represent proposed (but not detected) intermediates; 
numbering according to Figure S5 (see SI). 
 
Figure 4 Reconstructed LC-HR-MS ion chromatogram with the corresponding protonated exact 
masses indicating the given 5-MeO-2-Me-DALT metabolites in rat urine after 1 mg/kg BW dose 
administration; numbering according to Figures S1 and S2 (see SI). 
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Figure 1 Proposed metabolic pathways of 5-MeO-2-Me-DALT. Phase II metabolites: glucuronides (G), and 
sulfates (S). Structures in brackets represent proposed (but not detected) intermediates; numbering 
according to Figure S1 (see SI).  
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Figure 2 Proposed metabolic pathways of 5-MeO-2-Me-ALCHT. Phase II metabolites: glucuronides (G), and 
sulfates (S). Structures in brackets represent proposed (but not detected) intermediates; numbering 
according to Figure S3 (see SI).  
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Figure 3 Proposed metabolic pathways of 5-MeO-2-Me-DIPT. Phase II metabolites: glucuronides (G), and 
sulfates (S). Structures in brackets represent proposed (but not detected) intermediates; numbering 
according to Figure S5 (see SI).  
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Figure 4 Reconstructed LC-HR-MS ion chromatogram with the corresponding protonated exact masses 
indicating the given 5-MeO-2-Me-DALT metabolites in rat urine after 1 mg/kg BW dose administration; 
numbering according to Figures S1 and S2 (see SI).  
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